Features of the spectrum and the concentration of the products of purine and pyrimidine metabolism in thrombolytic therapy in patients with ischemic stroke

Cover Page

Cite item

Full Text

Abstract

Relevance. The disorders of energy metabolism, as a first response of brain tissue to ischemia, characterized by a change in the spectrum of purine and pyrimidine compounds, which are part of makroergic compounds and their metabolites. The aim of this work was to determine the spectrum and concentrations of purine and pyrimidine metabolism in patients with ischemic stroke (IS) before thrombolytic therapy (TLT).Materials and methods. The study included 24 patients (18 men and 6 women) with hemispheric IS, all was held TLT. All patients before the TLT was determined 18 range of purine and pyrimidine bases by the method of chromatography-tandem mass spectrometry (HPLC-MS/MS).Results. The spectral features of purine and pyrimidine bases in patients with a fatal outcome (FO) in the acute period of IS before TLT is the absence in serum of adenosine, desoxyadenosine, xanthine. The concentration of orotic acid in acute periodof IS associated with non-lethal hemorrhagic transformation (HT) and FO. The concentration of orotic acid less 2.29 mmol/l was associated with risk of developing, and above 90.6 mmol/l with non-lethal presence of HT, i.e. with a high probability of survival.

About the authors

O. V Lyang

N.I.Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation

Email: o.lyang@fedlab.ru
канд. биол. наук, науч. сотр. отд. экспериментально- теоретических исследований НИИ цереброваскулярной патологии и инсульта ГБОУ ВПО РНИМУ им. Н.И.Пирогова 117997, Russian Federation, Moscow, ul. Ostrovitianova, d. 1

V. N Fedorov

N.I.Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation

канд. мед. наук, науч. сотр. НИИ цереброваскулярной патологии и инсульта ГБОУ ВПО РНИМУ им. Н.И.Пирогова 117997, Russian Federation, Moscow, ul. Ostrovitianova, d. 1

A. G Kochetov

N.I.Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation

д-р мед. наук, зав. отд. экспериментально- теоретических исследований НИИ цереброваскулярной патологии и инсульта ГБОУ ВПО РНИМУ им. Н.И.Пирогова 117997, Russian Federation, Moscow, ul. Ostrovitianova, d. 1

N. A Shamalov

N.I.Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation

д-р мед. наук, зав. отд. диагностики и лечения инсульта НИИ цереброваскулярной патологии и инсульта ГБОУ ВПО РНИМУ им. Н.И.Пирогова 117997, Russian Federation, Moscow, ul. Ostrovitianova, d. 1

L. V Stakhovskaya

N.I.Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation

д-р мед. наук, проф., дир. НИИ цереброваскулярной патологии и инсульта ГБОУ ВПО РНИМУ им. Н.И.Пирогова 117997, Russian Federation, Moscow, ul. Ostrovitianova, d. 1

References

  1. Гусев Е.И., Мартынов М.Ю., Камчатнов П.Р. Ишемический инсульт. Современное состояние проблемы. Доктор.Ру. 2013; 5 (83): 7-12.
  2. Стаховская Л.В., Клочихина О.А., Богатырева М.Д., Коваленко В.В. Эпидемиология инсульта в России по результатам территориально - популяционного регистра (2009-2010). Журн. неврологии и психиатрии им. C.C.Корсакова. 2013; 113 (5): 4-10.
  3. Go A.S, Mozaffarian D, Roger V.L et al. Heart disease and stroke statistics - 2013 update: a report from the American Heart Association. Circulation 2013; 127 (1): e6-e245.
  4. Шамалов Н.А., Кустова М.А., Толмачев А.П. Тромболитическая терапия при ишемическом инсульте: предикторы безопасности и эффективности. Эффективная фармакотерапия. 2015; 39: 4-10.
  5. Zoppo G.J, Saver J.L, Jauch E.C et al. Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator. A science advisory from the American Heart Association. American Stroke Association. Stroke 2009; 40: 2945-8.
  6. Аragiannis А, Mikhailidis D, Tziomalos K et al. Serum Uric Acid as an Independent Predictor of Early Death After Acute Stroke. Circ J 2007; 71: 1120-7.
  7. Bos M.J. Uric acid is a risk factor for myocardial infarction and stroke: the Rotterdam study. Stroke 2006; 6: 1503-7.
  8. Cherubini A, Ruggiero C, Polidori M.C, Mecocci P. Potential markers of oxidative stress in stroke. Free Radic Biol Med 2005; 39 (7): 841-52.
  9. Hsiao G, Lin K.H, Chang Y et al. Protective mechanisms of inosine in platelet activation and cerebral ischemic damage. Arterioscler Thromb Vasc Biol 2005; 25 (9): 1998-2004.
  10. Системная тромболитическая терапия при ишемическом инсульте. Методические рекомендации. НИИ инсульта РГМУ. Авт.-сост. Н.А.Шамалов. Под ред. В.И.Скворцовой. М., 2007.
  11. Hacke W et al. ECASS Investigators. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008; 13: 1317-29.
  12. Brott T et al. Measurements of acute cerebral infarction: a clinical examination scale. Stroke 1989; 20: 864-70.
  13. СПСС (SPSS): искусство обработки информации. Под ред. А.Бююль, П.Цефель. М.-Спб.-Киев: DiaSoft, 2005.
  14. Орешникова С.Ф., Орешников Е.В. Особенности мочекислого обмена при развитии острой мозговой ишемии. Казанский мед. журн. 2008; 89 (1): 15-21.

Copyright (c) 2016 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies